About this trial
Cornea ectatic conditions such as keratoconus and post-LASIK (Laser In situ Keratomileusis) ectasia are disorders of the eye that are notorious for its uncontrolled progression over time, leading to loss of vision. There are valuable treatment options for controlling disease progression in mild to moderate stages of such disease. However in advanced cases and / or when contact lenses cannot be worn, surgery remains the only treatment option to rehabilitate vision. Most treatment options are highly invasive and represent significant risks. This study evaluates a novel corneal implant, Gebauer™ Lenticule to treat severe keratoconus or post-LASIK ectasia. This implant is derived from porcine collagen and intended for intra-stromal insertion. The Gebauer™ Lenticule is expected to improve the stability of the cornea while not impairing the vision. The procedure is an additive procedure after other treatment options have been exhausted. The procedure is reversible with removal of the implant (in the unexpected case of an adverse reaction), and vision may be restored to baseline.
The purpose of this study is to evaluate how well the implant is tolerated, it's safety profile, and how effective this new treatment option is in the treatment of keratoconus or post-LASIK ectasia.
Eligibility criteria
Qualifiers
Diagnosis of severe keratoconus in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty OR
Diagnosis of severe post-LASIK Ectasia in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty
In terms of general health, patients must be free of diagnosed terminal illnesses (life expectancy of greater than or equal to 2 years).
Patients must be aged 18 years or over and less than 80 years old
Disqualifiers
History or presence of any ocular pathologies that may interfere with the planned surgical treatment, including corneal epithelial problems
Previous corneal transplantation or corneal implant in the designated eye
Cataract with anticipated surgical intervention (IOL implantation) within 2 years
Active inflammation and/or infection of the eye or the eye lid
Trial design
Treatments tested in this trial
- Gebauer Lenticule
Treatment groups
Locations
1Sponsors and collaborators
The Royal Wolverhampton Hospitals NHS Trust
Lead sponsor
Gebauer Company
Collaborator